• Jump to main navigation
  • Jump to content
U of U Health
  • Billing & Insurance
  • MyChart
Search
  • Find A U of U Health Doctor
  • All U of U Health Services
  • All U of U Health Locations
  • For All U of U Health Patients & Visitors
    • Patient Services
      • Questions About Your Bill?
      • Urgent Care
      • Where to Stay
      • Patients & Family Services
      • Clinical Trials
    • University of Utah Hospital
      • University of Utah Hospital
      • Staying at the Hospital
      • Parking & Valet
      • Looking for Another Location?
    • General Questions
      • 801-581-2668
      • Find an Interpreter
      • About U of U Health
  • Billing & Insurance
  • MyChart
  • Search

Brock O'Neil, MD

  • Clinical Information
  • Academic Information
  • Clinical Trials
  • Patient Resources
  • Videos & News
No Rating Available?
In order to provide our patients and visitors with the most accurate and useful information, we only post physician satisfaction data when a physician has received a minimum of 30 returned surveys. For this provider, we have not yet received the minimum.
50 4.8 out of 5 Patient Rating

Languages Spoken: English, Italian

Brock O’Neil, MD is an assistant professor in the Division of Urology at the University of Utah School of Medicine and the Huntsman Cancer Institute. His clinical practice focuses on the surgical treatment of genitourinary malignancies including prostate, bladder, kidney, adrenal, testicular, penile and urethral cancers. He is an experienced robotic, laparoscopic, endoscopic, and open surgeon. Dr O’Neil completed medical school at the University of Rochester, residency at the University of Utah, and fellowship in Urologic Oncology at Vanderbilt University.

Clinical Locations

Huntsman Cancer Hospital

801-585-0250

Fax: (801) 585-3749

1950 Circle of Hope
Salt Lake City, UT  84112
Map

Specialties

  • Urology
  • Robotic Prostatectomy
  • Adrenal Cancer
  • Bladder Cancer
  • Kidney Cancer
  • Laparoscopy
  • Penile Cancer
  • Robotic Cystectomy and Diversion
  • Robotic Kidney Surgery
  • Testicular Cancer
  • Urinary Diversion
  • Blue Light Cystoscopy With Cysview
  • Genetic Counselor
  • Cystectomy
  • Cystoscopy
  • Prostate Cancer
  • Urologic Oncology

Board Certification and Academic Information

Academic Departments Surgery - Assistant Professor
Academic Divisions Urology
Board Certification American Board of Urology

Patient Rating

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Learn About Our Survey

Likelihood of recommending care provider

4.8/ 5

Care provider's explanation of condition/problem

4.8/ 5

Care provider's effort to include me in decisions

4.8/ 5

Wait time at clinic

4.5/ 5

Care provider's concern for questions & worries

4.8/ 5

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

UofU Patient March 24, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Very professional

UofU Patient February 21, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Very reassuring and helpful in planning my future medical care

UofU Patient February 05, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Drs. Hsu and O'Neil were very informative and answered all my questions. They got right to the point. It was a pleasure dealing with the both of them.

UofU Patient February 05, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

Was a very good experience.

UofU Patient January 16, 2022
SUGAR HOUSE HEALTH CENTER

5 out of 5 stars

Very good

UofU Patient January 15, 2022
HUNTSMAN CANCER CENTER

5 out of 5 stars

I feel very comfortable and well taken care of here.

UofU Patient December 14, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

No issues was a very brief visit once sern

UofU Patient November 21, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

We liked talking with the two doctors (department head and surgeon) who gave us lots if information and answers.

UofU Patient November 15, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

I recommended my brother to Dr. O'Neil

UofU Patient November 14, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

Always helpful in listening to issues

UofU Patient November 02, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

The very "good rating" applies to the doctor. The PA was "fair" to "good" primarily due to understandability (her accent and my hearing loss)

UofU Patient October 18, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

Dr. O'Neil is the best physician we have ever had and we are extremely grateful to have him on our care team.

UofU Patient October 09, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

Good

UofU Patient October 06, 2021
SUGAR HOUSE HEALTH CENTER

5 out of 5 stars

Good

UofU Patient September 20, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

Good appointment all my questions were answered and my options were clearly explained.

UofU Patient September 11, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

I always get the best care.

UofU Patient August 30, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

This was simply a cystoscopy to ensure my tumor had not grown back. Dr. O'Neill informed me of what he saw, that it was good news, and explained I would need to have a repeat cystoscopy in 9 months.

UofU Patient August 28, 2021
HUNTSMAN CANCER CENTER

4 out of 5 stars

Good

UofU Patient August 20, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

Fast and fun

UofU Patient August 16, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

You have DOCTORS - Wyoming has Human Vets

UofU Patient August 10, 2021
HUNTSMAN CANCER CENTER

3 out of 5 stars

Dr O'Neil was great. The PA was obviously pushing for surgery as the best option. Made me very questioning. These scores are for the PA

UofU Patient August 09, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

Great proposed treatment plans great teams and units very good treatment options and procedures.

UofU Patient August 06, 2021
HUNTSMAN CANCER CENTER

4 out of 5 stars

We waited a month for the zoom appointment and when we had our meeting the doctor hadn't even looked at the scans associated with our meeting. It would have been nice for them to had looked at everything and then had the meeting.

UofU Patient August 02, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

I feel very heard by Dr. O'Neil.

UofU Patient August 01, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

Fast and fun

UofU Patient July 16, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

Good

UofU Patient June 30, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

the doctor was great it was the wait tome

UofU Patient June 30, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

We just couldn't have asked for any better care.

UofU Patient June 18, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

Great people

UofU Patient June 09, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

Dr. O'neil is exceptional.

UofU Patient June 06, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

they really care for there patients truly

UofU Patient June 05, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

Very professiona?

UofU Patient May 29, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

explained everything, didn't rush and was very positive minded. put me at ease.

UofU Patient May 23, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

It now appears that Dr. O'Neil and his staff have saved my life. So whether or not I waited in the exam room for 5 minutes is not real important to me these days. Dr. O'Neil's honesty with me and his concern for my health have been outstanding.

UofU Patient May 13, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

very professional

UofU Patient May 05, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

All the staff was exceptional.

UofU Patient April 24, 2021
HUNTSMAN CANCER CENTER

4 out of 5 stars

Very professional listens and ask questions gives you the feeling things will be ok that my doctor cares.

UofU Patient April 09, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

Dr O'Neil is wonderful

UofU Patient April 09, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

This was a very positive experience even though it involved cancer. I feel like everyone truely cared about my well being.

UofU Patient March 29, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

ok

UofU Patient March 21, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

Very professional

UofU Patient March 19, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

Excellent

UofU Patient March 13, 2021
HUNTSMAN CANCER CENTER

3 out of 5 stars

Doc seemed to be in a hurry.

UofU Patient March 12, 2021
HUNTSMAN CANCER CENTER

4 out of 5 stars

It would have been helpful to explain the Rx instructions during our visit. Because the instructions were unusual, I questioned my pharmacist. He also found them unusual and simply referred me to my doctor. I messaged Dr O'Neal after picking up the prescription to ask for clarification which he then provided.

UofU Patient March 05, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

Given what I had the staff was super supportive

UofU Patient March 03, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

good

UofU Patient February 28, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

Everyone was great

UofU Patient February 19, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

Now that we're on a schedule and not just figuring out what's wrong, this is a smooth process.

UofU Patient February 07, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

All my questions were answered

UofU Patient January 29, 2021
HUNTSMAN CANCER CENTER

5 out of 5 stars

Dr. O'Neill was honest and caring about my situation every step of the way. And his surgical skills kept my pain and recovery times to an absolute minimum. Quite a doctor and quite a team!

Brock O’Neil, MD is an assistant professor in the Division of Urology at the University of Utah School of Medicine and the Huntsman Cancer Institute. His clinical practice focuses on the surgical treatment of genitourinary malignancies including prostate, bladder, kidney, adrenal, testicular, penile and urethral cancers. He is an experienced robotic, laparoscopic, endoscopic, and open surgeon. Dr O’Neil completed medical school at the University of Rochester, residency at the University of Utah, and fellowship in Urologic Oncology at Vanderbilt University.

Academic Locations

Research Statement

Dr. O’Neil co-directs the Urologic Oncology Research group. His research interests include measuring outcomes important to patients, improving the quality of surgical care for cancer, and understanding the effects of payment reform on cancer treatment. Dr. O’Neil is also interested in understanding the sociological forces that shape physician behavior and ultimately patient outcomes.

He is funded through the National Cancer Institute to study drivers of low-value cancer care with a focus on designing interventions to reduce this unnecessary care. He has a particular interest in improving the value of prostate cancer screening and runs a clinic that focuses on screening men who carry genetic mutations that place them at high risk for developing prostate cancer. He also receives NCI funding as part of a national study (CEASAR) to understand the impact of various prostate cancer treatments on patient outcomes.

Dr. O’Neil is a member of the Huntsman@Home evaluation committee, which aims to understand whether a novel hospital at home program provides value for patients treated at Huntsman. He also serves a Principle Investigator of several trials at Huntsman including the SOAR trial (Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate Cancer).

He has authored multiple book chapters, articles, commentaries, and abstracts and has published in peer-reviewed journals including the Journal of National Cancer Institute, JAMA Surgery, and the Journal of Urology.

Board Certification and Academic Information

Academic Departments Surgery - Assistant Professor
Academic Divisions Urology
Board Certification American Board of Urology

Education History

Fellowship Vanderbilt University
Urologic Oncology and Health Services Research
Fellow, 2016
Residency University of Utah
Urology
Resident, 2014
Internship University of Utah
General Surgery
Intern, 2010
Professional Medical University of Rochester School of Medicine & Dentistry
Doctor of Medicine with Distinction in Research
M.D., 2009
Undergraduate Brigham Young University
Exercise Science, Minor in Sociology
B.S., 2004

Selected Publications - Journal Articles

Journal Article

  1. Vehawn J, ONeil B (2021). Identifying Top Talent to Improve Prostatectomy Sexual Outcomes: Is the Juice Worth the Squeeze? JAMA Surg, 157(2), 144-145.
  2. Luckenbaugh AN, Wallis CJD, Huang LC, Wittmann D, Klaassen Z, Zhao Z, Koyama T, Laviana AA, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Hoffman KE, Penson DF, Barocas DA (2022). Association Between Treatment for Localized Prostate Cancer and Mental Health Outcomes. J Urol, 101097JU0000000000002370.
  3. Slade AD, Cardinal JR, Martin CR, Presson AP, Allen CD, Lowrance WT, Dechet CB, ONeil BB (2021). Feasibility of wearable activity trackers in cystectomy patients to monitor for postoperative complications. Curr Urol, 15(4), 209-213.
  4. Hunt TC, Ambrose JP, Haaland B, Kawamoto K, Dechet CB, Lowrance WT, Hanson HA, ONeil BB (2021). Decision fatigue in low-value prostate cancer screening. Cancer, 127(18), 3343-3353.
  5. Dorff TB, ONeil B, Hoffman KE, Lin DW, Loughlin KR, DallEra M (2021). 25-year perspective on prostate cancer: Conquering frontiers and understanding tumor biology. Urol Oncol, 39(9), 521-527.
  6. Mooney K, Titchener K, Haaland B, Coombs LA, ONeil B, Nelson R, McPherson JP, Kirchhoff AC, Beck AC, Ward JH (2021). Evaluation of Oncology Hospital at Home: Unplanned Health Care Utilization and Costs in the Huntsman at Home Real-World Trial. J Clin Oncol, 39(23), 2586-2593.
  7. Wallis CJD, Huang LC, Zhao Z, Penson DF, Koyama T, Conwill R, Tallman JE, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Barocas DA, Hoffman KE (2021). Association between pelvic nodal radiotherapy and patient-reported functional outcomes through 5 years among men undergoing external-beam radiotherapy for prostate cancer: An assessment of the comparative effectiveness analysis of surgery and radiation (CEASAR) cohort. Urol Oncol, 40, 56.e1-56.e8.
  8. Pasalic D, Barocas DA, Huang LC, Zhao Z, Koyama T, Tang C, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup AM, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Hoffman KE (2021). Five-year outcomes from a prospective comparative effectiveness study evaluating external-beam radiotherapy with or without low-dose-rate brachytherapy boost for localized prostate cancer. Cancer, 127(11), 1912-1925.
  9. Greenberg SE, Hunt TC, Ambrose JP, Lowrance WT, Dechet CB, ONeil BB, Tward JD (2021). Clinical Germline Testing Results of Men With Prostate Cancer: Patient-Level Factors and Implications of NCCN Guideline Expansion. JCO Precis Oncol, 5.
  10. Stone BV, Laviana AA, Luckenbaugh AN, Huang LC, Zhao Z, Koyama T, Conwill R, Hoffman K, Joyce DD, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2020). Patient-Reported Financial Toxicity Associated with Contemporary Treatment for Localized Prostate Cancer. J Urol, 205(3), 761-768.
  11. Lange SM, Ambrose JP, Flynn MC, Lowrance WT, Hanson HA, ONeil BB (2021). Prostate-specific antigen testing among young men: an opportunity to improve value. Cancer Med, 10(6), 2075-2079.
  12. Reisz PA, Laviana AA, Zhao Z, Huang LC, Koyama T, Conwill R, Hoffman K, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2020). Assessing the Quality of Surgical Care for Clinically Localized Prostate Cancer: Results from the CEASAR Study. J Urol, 204(6), 1236-1241.
  13. Huelster HL, Laviana AA, Joyce DD, Huang LC, Zhao Z, Koyama T, Hoffman KE, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg M, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2020). Radiotherapy after radical prostatectomy: Effect of timing of postprostatectomy radiation on functional outcomes. Urol Oncol, 38(12), 930.e23-930.e32.
  14. Klett DE, ONeil B (2020). Transurethral Resection of a Bladder Tumor in Pregnancy: Decidual Reaction Bladder Endometriosis. J Endourol Case Rep, 6(3), 132-134.
  15. Laviana AA, Zhao Z, Huang LC, Koyama T, Conwill R, Hoffman K, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2020). Development and Internal Validation of a Web-based Tool to Predict Sexual, Urinary, and Bowel Function Longitudinally After Radiation Therapy, Surgery, or Observation. Eur Urol, 78(2), 248-255.
  16. Tward JD, ONeil B, Boucher K, Kokeny K, Lowrance WT, Lloyd S, Cannon D, Stephenson RA, Agarwal N, Farr T, Petragallo R, Sherar NZ, Kunz I, Hofer A, Courdy S, Shrieve DC, Dechet C (2020). Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy. Clin Genitourin Cancer, 18(4), 274-283.e5.
  17. Armstrong JM, Martin CR, Dechet C, Morton K, Evans D, Ambrose J, Maughan BL, ONeil B, Lowrance W (2020). 18F-fluciclovine PET CT detection of biochemical recurrent prostate cancer at specific PSA thresholds after definitive treatment. Urol Oncol, 38(7), 636.e1-636.e6.
  18. Leiser CL, Taddie M, Hemmert R, Richards Steed R, VanDerslice JA, Henry K, Ambrose J, ONeil B, Smith KR, Hanson HA (2020). Spatial clusters of cancer incidence: analyzing 1940 census data linked to 1966-2017 cancer records. Cancer Causes Control, 31(7), 609-615.
  19. Oswald N, Lin T, Haaland B, Flynn M, Kawamoto K, Cooney KA, Lowrance W, Hanson HA, ONeil B (2020). Factors associated with appropriate and low-value PSA testing. Cancer Epidemiol, 66, 101724.
  20. Leiser CL, Anderson RE, Martin C, Hanson HA, ONeil B (2020). Combining Drive Time and Urologist Density to Understand Access to Urologic Care. Urology, 139, 78-83.
  21. Hanson HA, Leiser CL, ONeil B, Martin C, Gupta S, Smith KR, Dechet C, Lowrance WT, Madsen MJ, Camp NJ (2020). Harnessing Population Pedigree Data and Machine Learning Methods to Identify Patterns of Familial Bladder Cancer Risk. Cancer Epidemiol Biomarkers Prev, 29(5), 918-926.
  22. Jalali A, Martin C, Nelson RE, Vanneman ME, Martin BI, Cooney KA, Waitzman NJ, ONeil B (2019). Provider Practice Competition and Adoption of Medicare's Oncology Care Model. Med Care, 58(2), 154-160.
  23. Hoffman KE, Penson DF, Zhao Z, Huang LC, Conwill R, Laviana AA, Joyce DD, Luckenbaugh AN, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Koyama T, Barocas DA (2020). Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer. JAMA, 323(2), 149-163.
  24. Laviana AA, Hernandez A, Huang LC, Zhao Z, Koyama T, Conwill R, Hoffman K, Feurer ID, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Kaplan SH, Greenfield S, Penson DF, Barocas DA (2019). Interpretation of Domain Scores on the EPIC-How Does the Domain Score Translate into Functional Outcomes? J Urol, 202(6), 1150-1158.
  25. Hanson HA, Martin C, ONeil B, Leiser CL, Mayer EN, Smith KR, Lowrance WT (2019). The Relative Importance of Race Compared to Health Care and Social Factors in Predicting Prostate Cancer Mortality: A Random Forest Approach. J Urol, 202(6), 1209-1216.
  26. Nappi L, Thi M, Lum A, Huntsman D, Eigl BJ, Martin C, ONeil B, Maughan BL, Chi K, So A, Black PC, Gleave M, Wyatt AW, Lavoie JM, Khalaf D, Bell R, Daneshmand S, Hamilton RJ, Leao RRN, Nichols C, Kollmannsberger C (2019). Developing a Highly Specific Biomarker for Germ Cell Malignancies: Plasma miR371 Expression Across the Germ Cell Malignancy Spectrum. J Clin Oncol, 37(33), 3090-3098.
  27. Martin C, ONeil B, Lowrance W, Leiser C, Mayer E, Smith K, Hanson H (2019). The Relative Importance of Race Compared to Healthcare and Social Factors in Predicting Prostate Cancer Mortality: A Random Forest Approach. J Urol.
  28. Laviana A, Hernandez A, Zhao Z, Huang L, Koyama T, Conwill R, Feurer I, Hoffman K, Goodman M, Hamilton A, Wu X, Paddock L, Stroup A, Cooperberg M, Hashibe M, ONeil B, Penson D, Barocas D (2019). Interpretation of domain scores on the expanded prostate cancer index composite: How does the domain score translate into functional outcomes? J Urol.
  29. Martin C, Haaland B, Tward AE, Dechet C, Lowrance W, Stephenson RA, Hanson H, ONeil B (2018). Describing the Spectrum of Patient Reported Outcomes after Radical Prostatectomy: Providing Information to Improve Patient Counseling and Shared Decision Making. J Urol, 201(4), 751-758.
  30. Tward JD, Poppe MM, Hitchcock YJ, ONeil B, Albertson DJ, Shrieve DC (2018). Demographics, stage distribution, and relative roles of surgery and radiotherapy on survival of persons with primary prostate sarcomas. Cancer Med, 7(12), 6030-6039.
  31. ONeil B, Martin C, Kapron A, Flynn M, Kawamoto K, Cooney KA (2018). Defining low-value PSA testing in a large retrospective cohort: Finding common ground between discordant guidelines. Cancer Epidemiol, 56, 112-117.
  32. Martin C, Leiser CL, ONeil B, Gupta S, Lowrance WT, Kohlmann W, Greenberg S, Pathak P, Smith KR, Hanson HA (2017). Familial Cancer Clustering in Urothelial Cancer: A Population-Based Case-Control Study. J Natl Cancer Inst, 110(5), 527-533.
  33. ONeil B, Tyson M, Graves AJ, Barocas DA, Chang SS, Penson DF, Resnick MJ (2017). The influence of provider characteristics and market forces on response to financial incentives. Am J Manag Care, 23(11), 662-667.
  34. ONeil BB, Hoffman KE, Tasuki K, et al (2017). Patient Reported Comparative Effectiveness of Contemporary Intensity Modulated Radiotherapy Versus External Beam Radiotherapy of the Mid-1990's for Localized Prostate Cancer. Urol Pract.
  35. Martin C, Leiser CL, ONeil BB, Gupta S, Lowrance WT, Kohlmann W, Greenberg S, Pathak P, Smith KR, Hanson HA (2017). Familial Cancer Clustering in Urothelial Cancer: A population-Based Case-Control Study. J Natl Cancer Inst.
  36. ONeil B, Maughan B (2017). A More Common Massive Retroperitoneal Mass. JAMA Surg, 152(8), 802-803.
  37. ONeil B, Tyson MD, Graves AJ, Barocas DA, Chang SS, Penson DF, Resnick MJ (2017). The Influence of Provider Characteristics and Market Forces on Response to Financial Incentives.
  38. Sohn W, Graves AJ, Tyson MD, ONeil BB, Chang SS, Ni D, Barocas DA, Penson DF, Resnick MJ (2016). An Empiric Evaluation of the Effect of Variation in Intensity of Follow-Up for Surgically Treated Renal Neoplasms: Estimating Value in Survivorship Care. J Urol.
  39. ONeil B, Koyama T, Alvarez J, Conwill RM, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, Stanford JL, Stroup AM, Paddock LE, Wu XC, Stephenson RA, Resnick MJ, Barocas DA, Penson DF (2015). The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples. J Urol, 195(2), 321-9.
  40. ONeil BB, Graves AJ, Barocas DA, Chang SS, Penson DF, Resnick MJ (2015). Doing More for More: Unintended Consequences of Financial Incentives for Oncology Specialty Care. J Natl Cancer Inst, 108(2).
  41. ONeil BB, Koyama T, Alvarez J, Conwill RM, Albertsen PC, Cooperberg MR, Goodman M, Greenfield S, Hamilton AS, Hoffman KE, Hoffman RM, Kaplan SH, Stanford JL, Stroup AM, Paddock LE, Wu XC, Stephenson RA, Resnick MJ, Barocas DA, and Penson DF (2015). The Comparative Harms of Open and Robotic Prostatectomy in Population Based Samples. J Urol, 196.
  42. ONeil BB, Presson A, Gannon J, Stephenson RA, Lowrance W, Dechet CB, Tward JD, Myers JB, Brant WO (2014). Climacturia after definitive treatment of prostate cancer. J Urol, 191(1), 159-63.

Review

  1. Lange S, ONeil B (2021). Increasing the value of PSA through improved implementation. [Review]. Urol Oncol.

Conference Proceedings

  1. Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, Briganti A, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, ONeil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG (2020). Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. J Clin Oncol, United States, 38(24), 2798-2811.

Commentary

  1. Wallis CJD, Zhao Z, Huang LC, Penson DF, Koyama T, Kaplan SH, Greenfield S, Luckenbaugh AN, Klaassen Z, Conwill R, Goodman M, Hamilton AS, Wu XC, Paddock LE, Stroup A, Cooperberg MR, Hashibe M, ONeil BB, Hoffman KE, Barocas DA (2022). Association of Treatment Modality, Functional Outcomes, and Baseline Characteristics With Treatment-Related Regret Among Men With Localized Prostate Cancer. JAMA Oncol, 8(1), 50-59.

Editorial

  1. Hunt TC, ONeil BB (2020). Leveraging Behavioral Economics to Reduce Low-value Prostate Cancer Screening. Eur Urol, 77(4), 400-402.

Letter

  1. Hanson HA, Martin C, Leiser CL, ONeil B, Smith KR (2018). Response to K. Hemminki et al. [Letter to the editor]. J Natl Cancer Inst, 110(11), 1279.
  2. ONeil B, Lowrance WT, Heilbrun ME (2017). PET Scans With 18F-Fluorodeoxyglucose to Diagnose Adrenal Tumors. [Letter to the editor]. JAMA, 318(16), 1614.

Abstract

  1. ONeil B, Anderson R, Martin C, Leiser C, Hanson H (2019). A Novel Approach to Identify Disparities in Access to Urologic Care Based Upon Driving TIme [Abstract].
  2. Greenberg S, Tward J, Cooney K, Pappas L, ONeil B (2019). Germline genetic testing in men with prostate cancer: clinical characteristics and testing outcomes in a newly indicated population [Abstract].
  3. Armstrong J, Martin C, ONeil B, Dechet C, Morton K, Lowrance W (2018). Fluciclovine PET CT Detection of Biochemical Recurrent Prostate Cancer at Specific PSA Thresholds After Definitive Treatment [Abstract]. WSAUA.
  4. Jalali A, Nelson R, Vanneman M, Martin C, Martin B, Waitzman N, ONeil BB (06/25/2018). Provider Practice Competition and Adoption of Medicare's Oncology Care Model [Abstract]. AcademyHealth.
  5. Hanson H, Leiser C, Martin C, ONeil BB, Lowrance W, Alter O, Gupta S, Kohlman W, Greenberg W, Smith K, Camp N (04/2018). Redefining the Bladder Cancer Phenotype Using Patterns of Familial Risk [Abstract]. Journal of Urology, 199(4).
  6. Martin C, ONeil BB, Kapron A, Kawamoto K, Lowrance W, Flynn M, Cooney K (04/01/2018). Rate of Discordant PSA Testing Among Varied Guidelines: Identifying Targetable Inefficiencies in Our Health System [Abstract]. Journal of Urology, 199(4).
  7. Martin CM, ONeil BB, Kapron A, Flynn M, Kawamoto K, Lowrance WT, Cooney K (2017). Measuring PSA Screening Quality at the Health System Level: Potental Areas for Improvement [Abstract]. Society of Urologic Oncology.

News Articles

How Healthy Is Your Prostate?

Huntsman Cancer Institute News

How One Couple Made it through a Bladder Cancer Diagnosis during Pregnancy

Site Links

  • Find an Interpreter
  • About Us
  • Academics & Research
  • Billing
  • Jobs
  • Giving
  • Maps & Directions
  • Newsroom
  • Referring Providers

Helpful Links

  • Patient Rights & Responsibilities
  • Disclaimer
  • Privacy Statement
  • DNV GL Public Information Policy Statement
  • Non-Discrimination Policy
  • Surprise Billing Rights
  • Webmaster

Contact Us

University of Utah Health

50 North Medical Drive
Salt Lake City, UT 84132

801-581-2121

  • Facebook
  • Twitter
  • Youtube
  • Instagram

University of Utah

All clinical services and programs are part of University of Utah Health Hospitals and Clinics.

Copyright © 2022 University of Utah Health